相关实验视频

Updated: Jan 18, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

现实世界的数据显示,RAIR-(P) DTC中的顺序卡博桑提尼布治疗的有效性有限

Yara Maria Machlah^1,2, Lynn Marlene Srasra^1,3, Sarah Theurer^4,2

¹Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.

Endocrine-related cancer

|January 16, 2026

概括

卡博桑提尼布在抗放射性分化甲状腺癌 (RAIR-DTC) 和差分化甲状腺癌 (PDTC) 中显示出有限的现实有效性. 毒性很大,需要对这些晚期甲状腺癌进行谨慎的管理和新的治疗策略.

科学领域:

在瘤学瘤学.
内分泌学在内分泌学.
临床药理学临床药理学

背景情况:

卡博桑提尼布已获批准用于对放射性耐火的分化甲状腺癌 (RAIR-DTC) 在lenvatinib/sorafenib后的顺序治疗.
关于卡博赞提尼布 (cabozantinib) 的现实数据有限,特别是在差差分化的甲状腺癌 (PDTC) 中.

研究的目的:

评估卡博桑提尼布作为RAIR-DTC或PDTC患者的进一步线路治疗的实际疗效和安全性.
根据转换到卡博桑提尼布的原因 (毒性与进展) 来比较结果.

主要方法:

在先前的向治疗后,对RAIR-DTC或PDTC接受卡博桑提尼布治疗的成年患者进行了回顾性分析.
评估最佳总体反应,无进展生存期 (PFS),总生存期 (OS) 和不良事件.
分析包括19名患者的安全性和17名患者的疗效.

主要成果:

在24% (4/17) 的患者中观察到部分响应 (PR);由于lenvatinib毒性而切换患者的响应率更高 (3/4) 与进展 (1/13).
在DTC中,PFS的中位数为5.4个月,在PDTC中为3.6个月.
从开服卡博赞提尼布开始的中位数生存期为DTC13.5个月,PDTC15.8个月. 显著的毒性导致剂量修改 (31.6%) 或中止 (15.8%).

结论:

进一步的线路卡博桑提尼布在这个现实世界队列中在RAIR-(P) DTC,特别是PDTC中表现出有限的疗效.
由于先前治疗的毒性而启动卡博赞提尼布显示出比由于进展而启动的更有利的反应.
高毒性负担强调了需要谨慎的患者管理和开发高级甲状腺癌改善的治疗策略的需要.

关键词:

卡博桑提尼布 (cabozantinib) 是一种药物.有差异化的甲状腺癌.多激酶抑制剂的使用差异化的甲状腺癌是差异化的甲状腺癌.序列治疗疗法序列治疗

更多相关视频

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...